logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover

EXEL
Exelixis, Inc.
53.96
1 x 51.49
1 x 56.77
bid
ask
-
0.45
0.83%
1 @ 04:00 PM
54.50 +0.54 (1.00%)
Ytd23.11%
1y23.70%
53.25
day range
54.47
33.76
52 week range
55.91
Open54.34Prev Close54.41Low53.25High54.47Mkt Cap13.56B
Vol1.84MAvg Vol2.68MEPS3.02P/E17.87Forward P/E13.49
Beta0.43Short Ratio13.08Inst. Own106.81%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0450-d Avg49.90200-d Avg44.101yr Est49.50

EXEL News

This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday
benzinga.com
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

benzinga.com
Truist Securities Downgrades Exelixis to Hold, Raises Price Target to $54

Truist Securities analyst Gregory Renza downgrades Exelixis (NASDAQ:EXEL) from Buy to Hold and ra

benzinga.com
Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $55

Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and rai

Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst
benzinga.com
Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst

Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metasta

benzinga.com
Exelixis Reports Final STELLAR‑303 Analysis; Zanzalintinib In Combination With Tecentriq Showed Non‑

Exelixis, Inc. (NASDAQ:EXEL) today announced results from the final analysis of the dual primary end